Additional file 14: of M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma

Figure S8. Characterization, release behavior, and anti-proliferative capability of NPs in vitro. (A) DLS measurements of the size and PDI of PLGA-PEG(si-LINC00958) NPs for 1 week. (B) Zeta potential of PLGA-PEG(si-LINC00958) NPs. (C) In vitro release of LINC00958 siRNA from PLGA-PEG(si-LINC00958) NPs at 37 °C. (D) The knockdown efficiency of PLGA-PEG(si-LINC00958) NPs in HCCLM3 cells was evaluated using RT-qPCR. (E) CCK-8 assays were used to examine the in vitro anti-tumor capability of PLGA-PEG(si-LINC00958) NPs. **P < 0.01, ***P < 0.001.